Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium Despite Recent Treatment With IV Bisphosphonates
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Quebec
-
Québec, Quebec, Canada, G1S 4L8
- Research Site
-
Québec, Quebec, Canada, G1S 4L8
- Research Site
-
-
-
-
-
Limoges Cedex, France, 87042
- Research Site
-
Montpellier Cedex 5, France, 34298
- Research Site
-
Nantes Cedex 1, France, 44035
- Research Site
-
Villejuif cedex, France, 94805
- Research Site
-
-
-
-
-
Bologna, Italy, 40138
- Research Site
-
Firenze, Italy, 50139
- Research Site
-
Milano, Italy, 20162
- Research Site
-
Padova, Italy, 35128
- Research Site
-
Roma, Italy, 00128
- Research Site
-
-
-
-
-
Warszawa, Poland, 01-809
- Research Site
-
-
-
-
California
-
Encinitas, California, United States, 92024
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Research Site
-
-
Maryland
-
Salisbury, Maryland, United States, 21801
- Research Site
-
-
Michigan
-
Dearborn, Michigan, United States, 48124
- Research Site
-
Detroit, Michigan, United States, 48236
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Research Site
-
-
New York
-
Bronx, New York, United States, 10467
- Research Site
-
New York, New York, United States, 10065
- Research Site
-
Syracuse, New York, United States, 13210
- Research Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Research Site
-
Goldsboro, North Carolina, United States, 27534
- Research Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Hypercalcemia of Malignancy (HCM) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (CSC) > 12.5 mg/dL (3.1 millimoles /L) at screening by local laboratory
- Last IV bisphosphonate treatment must be >/= to 7 days and </= to 30 days before the screening corrected serum calcium
- Adults (>/=18 years)
- Adequate organ function as defined by the following criteria:
- serum aspartate aminotransferase (AST) </= 5 x upper limit of normal (ULN)
- serum alanine aminotransferase (ALT) </= 5 x upper limit of normal
- serum total bilirubin </= 2 x upper limit of normal
Exclusion Criteria:
- Evidence of benign hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease
- Receiving dialysis for renal failure
- Treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of the screening CSC
- Treatment with cinacalcet within 4 weeks prior to the date of the screening CSC
- Thirty days or less since receiving an investigational product (other than denosumab) or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study
- Known sensitivity to any of the products to be administered during the study (eg, mammalian derived products)
- Female subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment
- Female subject of childbearing potential is not willing to use 2 highly effective methods of contraception during treatment and for 7 months after the end of treatment
- Subject will not be available for follow-up assessment.
- Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: denosumab
Eligible subjects will receive denosumab at a dose of 120 mg subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
|
120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With a Response Within 10 Days of First Dose of Denosumab
Time Frame: 10 days
|
Response is defined as corrected serum calcium (CSC) ≤ 11.5 mg/dL, within 10 days after the first dose of denosumab.
For all CSC values, if albumin was < 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium [mg/dL] + (0.8 x (4 - serum albumin [g/dL]))
|
10 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With a Response by Visit
Time Frame: Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57
|
Response is defined as corrected serum calcium (CSC) ≤ 11.5 mg/dL, within 10 days after the first dose of denosumab.
For all CSC values, if albumin was < 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium [mg/dL] + (0.8 x (4 - serum albumin [g/dL]))
|
Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57
|
|
Percentage of Participants With a Complete Response by Visit
Time Frame: Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57
|
Response is defined as corrected serum calcium (CSC) ≤ 10.8 mg/dL (2.7 mmol/L).
For all CSC values, if albumin was < 4 g/dL, the following formula was used to calculate CSC: CSC = Total serum calcium [mg/dL] + (0.8 x (4 - serum albumin [g/dL])).
|
Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57
|
|
Time to Response
Time Frame: From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.
|
Time to Response was defined as the time period from study Day 1 to the first time post-baseline corrected serum calcium (CSC) ≤ 11.5 mg/dL. Participants were censored on the last CSC assessment day if no response was observed. If there was no post-baseline CSC assessment, time to response was censored on study Day 1. Time to response was analyzed using Kaplan-Meier methods. |
From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.
|
|
Time to Complete Response
Time Frame: From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.
|
Time to complete response was defined as the time period from study Day 1 to the first time post-baseline corrected serum calcium (CSC) was ≤ 10.8 mg/dL (2.7 mmol/L).
Participants were censored on the last CSC assessment day if no complete response was observed.
If there was no post-baseline CSC assessment, time to complete response was censored on study Day 1.
Time to complete response was analyzed using Kaplan-Meier methods.
|
From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.
|
|
Duration of Response
Time Frame: From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.
|
Duration of response is defined as the number of days from the first day of corrected serum calcium ≤ 11.5 mg/dL (2.9 millimoles/L) to the last day of corrected serum calcium ≤ 11.5 mg/dL.
Participants were censored on the last CSC assessment day if their CSC level never reached > 11.5 mg/dL after the first response.
If a participant had no CSC assessment after the first response, duration of response was set to zero and censored.
Duration of response was summarized for participants who achieved a response using the Kaplan-Meier method.
|
From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.
|
|
Duration of Complete Response
Time Frame: From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.
|
Duration of complete response is defined as the number of days from the first day of of corrected serum calcium ≤ 10.8 mg/dL (2.7 millimoles/L) to the last day of corrected serum calcium ≤ 10.8 mg/dL.
Participants were censored on the last CSC assessment day if their CSC level never reached > 10.8 mg/dL after the complete response.
If a participant had no CSC assessment after the complete response, duration of complete response was set to zero and censored.
Duration of complete response was summarized for participants who achieved a complete response using the Kaplan-Meier method.
|
From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.
|
|
Time to Relapse/Nonresponse of Hypercalcemia of Malignancy
Time Frame: From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.
|
Time to relapse/nonresponse was defined as the number of days from study Day 1 until the last day of CSC ≤ 11.5 mg/dL for all particiipants with relapse after the first response.
Participants were censored on the last CSC assessment day if their CSC level never reached > 11.5 mg/dL after first response.
For participants who never achieved response, time to relapse/nonresponse was set to zero.
Otherwise, if there was no post-baseline CSC assessment, time to relapse/nonresponse was censored on study Day 1.
Time to relapse/nonresponse was estimated using the Kaplan-Meier method.
|
From Day 1 until the end of study date or primary data cutoff date (13 September 2012), whichever occured first; median time on study was 1.8 months.
|
|
Change From Baseline in Corrected Serum Calcium
Time Frame: Baseline and Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57
|
Baseline and Days 2, 4, 8, 10, 15, 19, 23, 29, 36, 43, 50 and 57
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lung Diseases
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Parathyroid Diseases
- Head and Neck Neoplasms
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Calcium Metabolism Disorders
- Water-Electrolyte Imbalance
- Neoplasms
- Lymphoma
- Kidney Neoplasms
- Lung Neoplasms
- Multiple Myeloma
- Paraneoplastic Syndromes
- Endocrine Gland Neoplasms
- Parathyroid Neoplasms
- Hypercalcemia
- Physiological Effects of Drugs
- Bone Density Conservation Agents
- Denosumab
Other Study ID Numbers
Other Study ID Numbers
- 20070315
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.